U.S. FDA accepts New Drug Application for review and grants Priority Review for darolutamide

Ads

You May Also Like

Celsion Corporation Reports First Quarter 2017 Financial Results and Provides Business Update

LAWRENCEVILLE, N.J., May 12, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug ...

BeiGene to Present at the William Blair 2018 Growth Stock Conference

CAMBRIDGE, Mass. and BEIJING, China, June 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), ...

Fiasp® significantly improved overall blood sugar control in type 1 diabetes long-term

Lisbon, Portugal, 12 September 2017 ­­­- Fiasp® (fast-acting insulin aspart), the only approved, new-generation, ...